Product
Posoleucel
Aliases
Posoleucel (ALVR105), Viralym-M
5 clinical trials
8 indications
Indication
Adenovirus InfectionIndication
BK virus infectionIndication
Cytomegalovirus InfectionsIndication
Epstein-Barr Virus InfectionsIndication
Human Herpesvirus 6 InfectionIndication
Hemorrhagic CystitisIndication
BK Virus-associated NephropathyClinical trial
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 Posoleucel (ALVR105,Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell TransplantStatus: Terminated, Estimated PCD: 2024-01-31
Clinical trial
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)Status: Terminated, Estimated PCD: 2024-01-31
Clinical trial
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell TransplantationStatus: Terminated, Estimated PCD: 2024-01-31
Clinical trial
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell TransplantStatus: Completed, Estimated PCD: 2023-01-19
Clinical trial
Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 2-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred Posoleuccel (ALVR105) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK ViremiaStatus: Completed, Estimated PCD: 2022-10-20